Acinetobacter Pneumonia Therapeutics Market By Product Type (Targeted Antibiotics, Combination Antibiotic Therapies, Polymyxin-Based Therapies, Advanced Cephalosporins, Tetracycline Derivatives, Other Antimicrobial Therapies); By Treatment Modality (Monotherapy, Combination Therapy, Supportive Infection Management); By Resistance Profile (Carbapenem-Resistant Acinetobacter baumannii (CRAB), Multidrug-Resistant Acinetobacter baumannii (MDR), Carbapenem-Susceptible Acinetobacter Infections); By Care Setting (Tertiary Hospitals, Academic Medical Centers, General Acute-Care Hospitals, Intensive Care Units); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Acinetobacter Pneumonia Therapeutics Market: Resistance Shifts Hospital Spending Toward Targeted Antibiotics

The Global Acinetobacter Pneumonia Therapeutics Market is estimated at USD 350 million in 2025 and is projected to reach approximately USD 730 million by 2032, expanding at an approximate CAGR of 11.0% during the forecast period, according to Strategic Market Research.

 

Treatment strategies for Acinetobacter pneumonia, particularly infections caused by multidrug-resistant (MDR) and carbapenem-resistant Acinetobacter baumannii (CRAB) strains, are increasingly centered on targeted and combination therapies. Sulbactam-durlobactam remains the key FDA-approved targeted option, while emerging agents such as zosurabalpin are advancing through clinical development with potential to address persistent treatment challenges.

 

CDC surveillance across selected U.S. areas covering 19.49 million people identified 368 CRAB cases in 2021. Pneumonia was recorded in 110 cases, or 29.9%, while 161 cases involved lower-respiratory specimens. Forty of those 161 patients died within 30 days, producing a 24.9% mortality rate. These figures are not national totals, but they show that respiratory disease is a material and clinically severe component of the CRAB burden.

 

A broader U.S. hospital study identified 7,270 Acinetobacter baumannii-positive encounters between 2018 and 2022, including 2,708 CRAB encounters. Respiratory specimens represented 39.4% of single-site CRAB cultures, while in-hospital mortality reached 20.5%. CRAB incidence in the participating hospitals increased from 0.39 to 0.53 cases per 100 hospitalization encounters during the study period. The data do not represent a national market-growth rate, but they indicate rising resistant-case pressure inside acute-care systems where premium antibiotics are purchased.

 

The Revenue Engine: Resistance Replaces Generic Volume with Premium Treatment

Carbapenem resistance changes the economics of treatment. Susceptible infections can often be managed with established beta-lactams, carbapenems or other generic agents. CRAB narrows the active treatment pool and increases reliance on combination regimens, specialist oversight and higher-value products. The commercial shift is visible in current treatment guidance.

IDSA recommends a sulbactam-containing regimen for CRAB and identifies sulbactam-durlobactam combined with imipenem-cilastatin or meropenem as the preferred approach. High-dose ampicillin-sulbactam with another active agent is positioned as an alternative when sulbactam-durlobactam is unavailable. Cefiderocol, polymyxin B, minocycline and tigecycline remain potential combination components, but their roles are more selective. IDSA also advises against routine adjunctive nebulized antibiotics for CRAB pneumonia because clinical benefit has not been demonstrated and pulmonary distribution can be inconsistent.

This hierarchy is redistributing value toward targeted sulbactam-based therapy. Older polymyxins remain relevant because they are widely available and comparatively inexpensive, but nephrotoxicity and dosing complexity weaken their long-term commercial position. In the pivotal comparison cited by IDSA, 28-day mortality was 19% with sulbactam-durlobactam versus 32% with colistin-based treatment. Clinical cure was 62% versus 40%, and nephrotoxicity was 13% versus 38%. The comparator is not the only available CRAB regimen, yet the renal-safety difference gives hospitals an economic reason to consider a premium agent when kidney injury could extend intensive-care treatment or complicate recovery.

 

Xacduro Establishes the Premium Pathogen-Specific Segment

The FDA approved Xacduro in May 2023 for adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex. Its narrow pathogen-specific label distinguishes it from broad Gram-negative antibiotics and aligns commercial use with confirmed or strongly suspected Acinetobacter infection.

Commercial uptake has been rapid relative to the size of the niche. Innoviva reported U.S. Xacduro net sales of USD 33.4 million in 2025, up from USD 14.7 million in 2024, and USD 11.6 million in the first quarter of 2026. The 2024–2025 increase equals approximately 127% based on an SMR calculation. Revenue cannot be converted into treated patients because vial volumes, discounts and treatment-course data are not public, but the sales progression confirms that hospital formularies are converting the clinical preference into recurring product demand.

Geographic expansion adds a second growth route. China approved sulbactam-durlobactam through priority review in 2025, opening access to a major hospital market where local reimbursement and formulary inclusion will determine the pace of adoption. Innoviva also signed a June 2026 distribution and licensing agreement with Dr. Reddy’s covering South and Central America, the Caribbean, Russia and CIS countries. Dr. Reddy’s will manage local development, approvals and commercialization, while Innoviva is eligible for upfront, milestone and royalty payments. The partnership reduces the cost of building separate regional hospital sales operations and gives Xacduro access to markets with high reported carbapenem resistance.

 

Market Segmentation: Value Concentrates in CRAB, VABP and Tertiary Hospitals

Sulbactam-based therapies formed the largest treatment segment in 2025, accounting for an estimated 43.0% of the market, or USD 150.5 million. Their share is projected to rise to approximately 49.0%, or USD 357.7 million, by 2032 as Xacduro penetration increases and high-dose sulbactam combinations remain central to CRAB protocols. Polymyxin-based therapies held an estimated 19.0% share, equal to USD 66.5 million, in 2025. Their share is expected to fall to about 13.0% by 2032, although revenue could still reach USD 94.9 million as resistant infections remain common in markets with limited access to newer drugs.

Cefiderocol and other advanced cephalosporin therapies represented an estimated 15.0%, or USD 52.5 million, in 2025 and could reach 17.0%, or USD 124.1 million, by 2032. Tetracycline derivatives accounted for approximately 13.0%, or USD 45.5 million, while carbapenems and other conventional beta-lactams represented the remaining 10.0%, or USD 35.0 million. These figures are SMR-modeled allocations because manufacturers do not report Acinetobacter pneumonia revenue by drug class.

By resistance profile, carbapenem-resistant and other multidrug-resistant infections generated an estimated 72.0% of 2025 revenue, equivalent to USD 252.0 million. Their share is projected to increase to 78.0%, or USD 569.4 million, by 2032. This segment commands a disproportionate share of spending because resistant cases require combinations, restricted drugs and longer hospital management. Carbapenem-susceptible infections represented the remaining USD 98.0 million in 2025 and are projected to reach USD 160.6 million by 2032.

Ventilator-associated bacterial pneumonia accounted for an estimated 59.0% of market revenue, or USD 206.5 million, in 2025 and could rise to 61.0%, or USD 445.3 million, by 2032. Non-ventilator hospital-acquired pneumonia represented USD 143.5 million in 2025. Tertiary hospitals, academic medical centers and advanced ICUs controlled approximately 67.0% of demand, or USD 234.5 million, because they manage the largest concentration of ventilated and highly resistant cases. Their share is projected to reach 70.0% by 2032. General acute-care hospitals held about 29.0%, while other institutional settings represented approximately 4.0%.

 

Regional Revenue: North America Leads, Asia-Pacific Gains Share

North America accounted for an estimated 40.0% of global revenue in 2025, equivalent to USD 140.0 million. Early Xacduro and Fetroja access, established stewardship programs and relatively developed reimbursement pathways support the region’s lead. Its share is expected to moderate to 37.0%, or USD 270.1 million, by 2032 as adoption broadens elsewhere.

Europe held approximately 28.0%, or USD 98.0 million, in 2025 and is projected to reach USD 197.1 million by 2032. ECDC reported carbapenem resistance in 73.9% of Acinetobacter baumannii isolates from participating European ICUs in 2022. More recent regional surveillance also shows major country variation, with at least 50% resistance reported by 18 of 37 countries submitting 2024 Acinetobacter data. This creates strong need but uneven commercial opportunity, favouring targeted deployment in southern and eastern European hospital systems.

Asia-Pacific represented an estimated 25.0%, or USD 87.5 million, in 2025 and is projected to reach 29.0%, or USD 211.7 million, by 2032. China’s Xacduro approval, cefiderocol expansion and investment in tertiary-care infrastructure support the increase. Latin America accounted for approximately 4.0% and the Middle East and Africa for 3.0%. Their combined opportunity will depend on registration, tender access, diagnostic capacity and affordable institutional pricing.

 

Competitive Landscape: Branded Leaders Sit Above a Fragmented Generic Base

The market remains moderately fragmented because two prominent branded platforms compete with numerous generic injectable suppliers. SMR estimates that Shionogi held approximately 15.0% of the 2025 market, equal to USD 52.5 million, through cefiderocol. This allocation includes only the estimated Acinetobacter pneumonia-related portion of Fetroja and Fetcroja sales. Shionogi reported that cefiderocol was marketed in 26 countries and regions by April 2025, while its U.S. business continued expanding around Fetroja.

Innoviva Specialty Therapeutics and Entasis held an estimated 11.0%, or USD 38.5 million. The estimate is anchored by disclosed U.S. Xacduro sales of USD 33.4 million and recognizes smaller international contributions. Innoviva has the strongest direct niche position because Xacduro is specifically approved for susceptible Acinetobacter HABP and VABP and occupies the preferred CRAB position in U.S. guidance.

SMR estimates Pfizer at approximately 8.0%, Fresenius Kabi at 6.0%, Sandoz at 5.0% and Aurobindo Pharma at 4.0%, based on their relative positions in hospital-administered generic antibiotics and institutional injectable distribution. Other regional and generic manufacturers collectively accounted for approximately 51.0%. These shares are SMR estimates rather than reported company figures because manufacturers do not disclose sales specifically generated from Acinetobacter pneumonia.

 

Pipeline Pressure Creates the Next Competitive Cycle

Pipeline investment is moving toward pathogen-specific and nontraditional approaches. WHO retained carbapenem-resistant Acinetobacter baumannii among its critical-priority pathogens in the 2024 bacterial priority list, maintaining policy and funding attention around new therapies.

Omnix Medical’s OMN6 entered Phase II development for hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii, with the first patient dosed in 2026. The antimicrobial peptide physically disrupts bacterial membranes rather than relying on conventional enzyme targets. Omnix raised USD 25 million in Series C funding to support Phase II proof-of-concept work, regulatory activity and manufacturing scale-up. Its commercial potential will depend on clinical efficacy, safety, production cost and whether hospitals view it as a replacement for or companion to established combinations.

Shionogi is also investing beyond cefiderocol. The company opened the Shionogi Qpex Lab in San Diego in April 2025 and is advancing an injectable combination of cefiderocol with xeruborbactam. This strategy could extend its position from a single premium antibiotic into a broader resistant Gram-negative platform.

 

Strategic Outlook: Growth Depends on Value per Case, Not Prescription Volume

The Acinetobacter Pneumonia Therapeutics Market is moving from generic rescue therapy toward targeted, susceptibility-supported hospital products. Xacduro currently has the strongest direct CRAB positioning, while cefiderocol remains important in refractory and broader resistant Gram-negative infections. Generic sulbactam, polymyxin and tetracycline combinations will continue limiting premium penetration, particularly in price-sensitive health systems.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2025 – 2032
Market Size Value in 2025	USD 350 Million
Revenue Forecast in 2032	USD 730 Million
Overall Growth Rate	CAGR of 11.0% (2025 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2025 – 2032)
By Product Type	Targeted Antibiotics; Combination Antibiotic Therapies; Polymyxin-Based Therapies; Advanced Cephalosporins; Tetracycline Derivatives; Other Antimicrobial Therapies
By Treatment Modality	Monotherapy; Combination Therapy; Supportive Infection Management
By Resistance Profile	Carbapenem-Resistant Acinetobacter baumannii (CRAB); Multidrug-Resistant Acinetobacter baumannii (MDR); Carbapenem-Susceptible Acinetobacter Infections
By Care Setting	Tertiary Hospitals; Academic Medical Centers; General Acute-Care Hospitals; Intensive Care Units
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Rising CRAB and MDR Infection Burden	Increasing prevalence of carbapenem-resistant and multidrug-resistant Acinetobacter infections is shifting hospital spending toward targeted antibiotics and combination treatment approaches.
Market Drivers – Demand for Pathogen-Specific Therapies	Growing clinical preference for susceptibility-guided therapies and FDA-approved targeted treatments is creating opportunities for premium antimicrobial products.
Market Drivers – Hospital-Acquired and Ventilator-Associated Pneumonia Burden	Rising cases of ICU-associated infections, ventilator-associated bacterial pneumonia, and complex hospital infections are increasing demand for advanced therapeutic options.
Customization Option	Available upon request